HPSE and cancer: These heparin mimetics that inhibit heparanase enzymatic activity are being evaluated in numerous clinical trials for various types of cancer, and appear to be well tolerated and also beneficial in combination with conventional anticancer drugs, thus providing a strong rationale for applying anti-heparanase therapy.